What percentage of patients with LCIS have synchronous breast cancer?

The correct percentage of patients with Lobular Carcinoma In Situ (LCIS) who have synchronous breast cancer is 5%. LCIS is considered a marker for increased risk for breast cancer, rather than a true precursor in the same way that Ductal Carcinoma In Situ (DCIS) is viewed.

Patients diagnosed with LCIS have an elevated risk of developing invasive breast cancer in both breasts over time. While the risk of synchronous cancer is not negligible, the figure of approximately 5% highlights the relatively lower incidence compared to other conditions. It is essential to recognize that the risk of developing breast cancer later on remains significantly higher for women with LCIS compared to those without it.

Understanding the implications of these statistics can help in managing patient surveillance and treatment strategies, particularly for those diagnosed with LCIS, who may need enhanced screening protocols.